Your browser is no longer supported. Please, upgrade your browser.
Settings
PPD PPD, Inc. daily Stock Chart
PPD [NASD]
PPD, Inc.
Index- P/E89.47 EPS (ttm)0.19 Insider Own0.50% Shs Outstand340.31M Perf Week17.08%
Market Cap5.79B Forward P/E12.03 EPS next Y1.41 Insider Trans- Shs Float340.31M Perf Month-40.48%
Income- PEG5.85 EPS next Q0.23 Inst Own80.71% Short Float0.29% Perf Quarter-
Sales3.85B P/S1.50 EPS this Y-49.70% Inst Trans- Short Ratio0.31 Perf Half Y-
Book/sh-9.66 P/B- EPS next Y17.95% ROA- Target Price32.54 Perf Year-
Cash/sh1.19 P/C14.34 EPS next 5Y15.30% ROE- 52W Range10.61 - 33.23 Perf YTD-43.33%
Dividend- P/FCF- EPS past 5Y- ROI10.20% 52W High-48.84% Beta-
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low60.23% ATR2.93
Employees23000 Current Ratio1.00 Sales Q/Q12.80% Oper. Margin- RSI (14)- Volatility19.91% 16.31%
OptionableYes Debt/Eq- EPS Q/Q619.00% Profit Margin- Rel Volume0.77 Prev Close19.91
ShortableYes LT Debt/Eq- EarningsMar 04 AMC Payout- Avg Volume3.20M Price17.00
Recom1.80 SMA20-22.66% SMA50-33.99% SMA200-33.99% Volume2,451,318 Change-14.62%
Mar-23-20Upgrade Jefferies Hold → Buy $30.50 → $20
Mar-02-20Initiated William Blair Outperform
Mar-02-20Initiated UBS Buy $34
Mar-02-20Initiated Robert W. Baird Outperform $35
Mar-02-20Initiated Morgan Stanley Overweight $34
Mar-02-20Initiated Mizuho Buy $32
Mar-02-20Initiated JP Morgan Overweight $35
Mar-02-20Initiated Jefferies Hold $30.50
Mar-02-20Initiated Goldman Buy $34
Mar-02-20Initiated Evercore ISI Outperform $33
Mar-02-20Initiated Deutsche Bank Buy $33
Mar-02-20Initiated Credit Suisse Outperform $32
Mar-02-20Initiated Citigroup Buy $34
Mar-02-20Initiated BofA/Merrill Buy $33
Mar-02-20Initiated Barclays Overweight $33
Mar-17-20 09:00AM  PPD Named CIO 100 Award Winner for Clinical Research Data-Visualization Tool Business Wire
Mar-10-20 04:01PM  PPD Announces Cancellation of Fireside Chat and Webcast at the Barclays Global Healthcare Conference 2020 Business Wire
Mar-05-20 04:01PM  PPD to Participate in Barclays Global Healthcare Conference Business Wire
Mar-04-20 04:01PM  PPD Reports Fourth Quarter and Full Year 2019 Results Business Wire
Mar-03-20 10:03AM  Goldman Sachs: 3 IPO Stocks to Snap Up Now TipRanks
Mar-02-20 02:31PM  Credit Markets Ignore Equity Rally With Fear Gauges Flashing Red Bloomberg
Feb-25-20 09:15AM  PPD Recognized for Leadership in Employee Training and Development Business Wire -5.14%
Feb-20-20 09:00AM  PPD Announces Fourth Quarter and Full Year 2019 Earnings Release Date and Conference Call Business Wire
Feb-17-20 10:36AM  Weekly CEO Buys Highlight GuruFocus.com
Feb-16-20 04:07PM  Top Insider Buys Highlight for the Week of Feb. 14 GuruFocus.com
Feb-07-20 04:17PM  Casper Sleep Slips Below IPO Price on Second Day as Public Firm Bloomberg
Feb-06-20 04:33PM  Casper Ends Public Debut Worth Less Than Half Private Valuation Bloomberg
11:15AM  Drug research company PPD' shares soar 14% in trading debut MarketWatch
Feb-05-20 07:44PM  PPD Inc. Raises $1.62 Billion in 2020s Biggest U.S. IPO Bloomberg
06:08PM  PPD prices IPO at high end of range MarketWatch
06:00PM  Casper to Price IPO Shares at $12, Bottom of Lower Range Bloomberg
Feb-01-20 02:34PM  IPO market braces for first billion-dollar deals of 2020and Casper wont be one of them MarketWatch
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates in two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.